OptimizeRx (OPRX) News Today $4.87 -0.31 (-5.98%) Closing price 04:00 PM EasternExtended Trading$4.87 0.00 (0.00%) As of 04:38 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 Time Period OptimizeRx Sets Fourth Quarter and Full Year 2024 Financial Results Conference Call for March 12, 2025, at 8:30 a.m. ETFebruary 27, 2025 | globenewswire.comOptimizeRx Co. (NASDAQ:OPRX) Receives Consensus Recommendation of "Moderate Buy" from BrokeragesFebruary 27, 2025 | americanbankingnews.comOptimizeRx Co. (NASDAQ:OPRX) Receives Consensus Rating of "Moderate Buy" from AnalystsOptimizeRx Co. (NASDAQ:OPRX - Get Free Report) has been given an average recommendation of "Moderate Buy" by the nine brokerages that are presently covering the firm, MarketBeat reports. Three analysts have rated the stock with a hold rating and six have assigned a buy rating to the company. TheFebruary 22, 2025 | marketbeat.comOne OptimizeRx Insider Raised Their Stake In The Previous YearFebruary 12, 2025 | uk.finance.yahoo.comOptimizeRx's (OPRX) "Market Outperform" Rating Reaffirmed at JMP SecuritiesJMP Securities reiterated a "market outperform" rating and set a $8.00 price objective on shares of OptimizeRx in a report on Thursday.February 6, 2025 | marketbeat.comOptimizeRX edges higher as holder pushes firm to explore a saleFebruary 6, 2025 | msn.comJPMorgan Chase & Co. Sells 104,750 Shares of OptimizeRx Co. (NASDAQ:OPRX)JPMorgan Chase & Co. reduced its position in shares of OptimizeRx Co. (NASDAQ:OPRX - Free Report) by 93.1% in the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 7,783 shares of the companyFebruary 4, 2025 | marketbeat.comOptimizeRx Co. (NASDAQ:OPRX) Receives Average Rating of "Moderate Buy" from AnalystsOptimizeRx Co. (NASDAQ:OPRX - Get Free Report) has earned an average recommendation of "Moderate Buy" from the nine research firms that are covering the stock, MarketBeat.com reports. Three investment analysts have rated the stock with a hold rating and six have assigned a buy rating to the compaJanuary 28, 2025 | marketbeat.comStrong week for OptimizeRx (NASDAQ:OPRX) shareholders doesn't alleviate pain of three-year lossJanuary 24, 2025 | finance.yahoo.comOptimizeRx (OPRX) was downgraded to a Hold Rating at Stifel NicolausJanuary 13, 2025 | markets.businessinsider.comOptimizeRx downgraded to Sector Perform from Outperform at RBC CapitalJanuary 8, 2025 | markets.businessinsider.comOptimizeRx (OPRX) was downgraded to a Hold Rating at RBC CapitalJanuary 8, 2025 | markets.businessinsider.comOptimizeRx downgraded to "sector perform" by RBC amid slower growth outlookJanuary 8, 2025 | msn.comRBC Capital Downgrades OptimizeRx (OPRX)January 8, 2025 | msn.comRoyal Bank of Canada Reaffirms "Sector Perform" Rating for OptimizeRx (NASDAQ:OPRX)Royal Bank of Canada restated a "sector perform" rating and set a $6.00 price target (down previously from $7.00) on shares of OptimizeRx in a report on Wednesday.January 8, 2025 | marketbeat.comOptimizeRx Co. (NASDAQ:OPRX) Given Average Rating of "Moderate Buy" by BrokeragesOptimizeRx Co. (NASDAQ:OPRX - Get Free Report) has been assigned a consensus recommendation of "Moderate Buy" from the nine analysts that are covering the stock, Marketbeat.com reports. Two investment analysts have rated the stock with a hold rating and seven have given a buy rating to the companyJanuary 3, 2025 | marketbeat.comIs There An Opportunity With OptimizeRx Corporation's (NASDAQ:OPRX) 49% Undervaluation?January 2, 2025 | uk.finance.yahoo.comLake Street reiterates Buy on OptimizeRx after ‘surprising’ CEO departureDecember 25, 2024 | finance.yahoo.comStifel Nicolaus Keeps Their Buy Rating on OptimizeRx (OPRX)December 24, 2024 | markets.businessinsider.comOptimizeRx price target lowered to $13 from $17 at B. RileyDecember 24, 2024 | markets.businessinsider.comOptimizeRx's (OPRX) Buy Rating Reaffirmed at Lake Street CapitalLake Street Capital reissued a "buy" rating and issued a $11.00 price target on shares of OptimizeRx in a research note on Tuesday.December 24, 2024 | marketbeat.comB. Riley Cuts OptimizeRx (NASDAQ:OPRX) Price Target to $13.00B. Riley dropped their target price on OptimizeRx from $17.00 to $13.00 and set a "buy" rating for the company in a research report on Tuesday.December 24, 2024 | marketbeat.comOptimizeRx announces departure of CEO Febbo, appoint Silvestro as interim CEODecember 24, 2024 | markets.businessinsider.comOptimizeRx affirms FY24 guidance, sees revenue, adjusted EBITDA at higher endDecember 23, 2024 | markets.businessinsider.comOptimistic Buy Rating for OptimizeRx Amid Leadership Transition and Strong Financial OutlookDecember 23, 2024 | markets.businessinsider.comOptimizeRx CEO William Febbo To Step Down; Names Stephen Silvestro As Interim CEODecember 23, 2024 | markets.businessinsider.comOptimizeRx Announces Departure of CEO William Febbo and Appointment of Stephen Silvestro as Interim CEODecember 23, 2024 | globenewswire.comStephens & Co. Initiates Coverage of OptimizeRx (OPRX) with Equal-Weight RecommendationDecember 21, 2024 | msn.comOptimizeRx (NASDAQ:OPRX) Earns Equal Weight Rating from Analysts at StephensStephens started coverage on OptimizeRx in a report on Friday. They set an "equal weight" rating and a $5.50 target price on the stock.December 20, 2024 | marketbeat.comAnalysts Conflicted on These Healthcare Names: OptimizeRx (OPRX) and Universal Health (UHS)December 17, 2024 | markets.businessinsider.comInsider Buying: OptimizeRx Co. (NASDAQ:OPRX) CEO Buys 20,000 Shares of StockDecember 17, 2024 | insidertrades.comWilliam J. Febbo Acquires 20,000 Shares of OptimizeRx Co. (NASDAQ:OPRX) StockOptimizeRx Co. (NASDAQ:OPRX - Get Free Report) CEO William J. Febbo purchased 20,000 shares of OptimizeRx stock in a transaction on Thursday, December 12th. The stock was bought at an average price of $5.01 per share, with a total value of $100,200.00. Following the transaction, the chief executive officer now owns 601,253 shares of the company's stock, valued at approximately $3,012,277.53. This represents a 3.44 % increase in their ownership of the stock. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link.December 16, 2024 | marketbeat.comOptimizeRx Co. (NASDAQ:OPRX) Given Consensus Recommendation of "Moderate Buy" by BrokeragesOptimizeRx Co. (NASDAQ:OPRX - Get Free Report) has been assigned a consensus recommendation of "Moderate Buy" from the seven analysts that are currently covering the firm, MarketBeat reports. One equities research analyst has rated the stock with a hold rating and six have given a buy rating to tDecember 9, 2024 | marketbeat.comOptimizeRx to Participate in Upcoming Investor ConferencesNovember 18, 2024 | globenewswire.comOptimizeRx price target lowered to $8 from $13 at StifelNovember 15, 2024 | markets.businessinsider.comOptimizeRx price target lowered to $8 from $16 at JMP SecuritiesNovember 15, 2024 | markets.businessinsider.comOptimizeRx (OPRX) Gets a Buy from Stifel NicolausNovember 15, 2024 | markets.businessinsider.comOptimizeRx's (OPRX) "Buy" Rating Reiterated at Roth MkmRoth Mkm reiterated a "buy" rating and set a $16.00 target price (down previously from $20.00) on shares of OptimizeRx in a research note on Thursday.November 14, 2024 | marketbeat.comStifel Nicolaus Cuts OptimizeRx (NASDAQ:OPRX) Price Target to $8.00Stifel Nicolaus decreased their target price on shares of OptimizeRx from $13.00 to $8.00 and set a "buy" rating on the stock in a research note on Thursday.November 14, 2024 | marketbeat.comOptimizeRx (NASDAQ:OPRX) Given New $5.00 Price Target at BarclaysBarclays dropped their price objective on OptimizeRx from $11.00 to $5.00 and set an "equal weight" rating on the stock in a research report on Thursday.November 14, 2024 | marketbeat.comJMP Securities Lowers OptimizeRx (NASDAQ:OPRX) Price Target to $8.00JMP Securities lowered their price objective on OptimizeRx from $16.00 to $8.00 and set a "market outperform" rating for the company in a research report on Thursday.November 14, 2024 | marketbeat.comOptimizeRx Reports Strong Revenue Growth in Q3 2024November 14, 2024 | markets.businessinsider.comOptimizeRx: Buy Rating Affirmed Amid Financial Efficiency and Business Model ShiftNovember 14, 2024 | markets.businessinsider.comOptimizeRx Corporation (OPRX) Q3 2024 Earnings Call TranscriptNovember 13, 2024 | seekingalpha.comOptimizeRx Reports Third Quarter 2024 Financial ResultsNovember 13, 2024 | markets.businessinsider.comPreview: OptimizeRx's EarningsNovember 13, 2024 | benzinga.comOptimizeRx (OPRX) Scheduled to Post Quarterly Earnings on WednesdayOptimizeRx (NASDAQ:OPRX) will be releasing earnings after the market closes on Wednesday, November 13, Zacks reports. (Register for Conference Call at http://mmm.wallstreethorizon.com/u.asp?u=643153)November 6, 2024 | marketbeat.comOptimizeRx (OPRX) Set to Announce Quarterly Earnings on WednesdayOptimizeRx (NASDAQ:OPRX) will be releasing earnings after the market closes on Wednesday, November 13, Zacks reports. (Register for Conference Call at http://mmm.wallstreethorizon.com/u.asp?u=643153)November 6, 2024 | marketbeat.comRice Hall James & Associates LLC Acquires 119,306 Shares of OptimizeRx Co. (NASDAQ:OPRX)Rice Hall James & Associates LLC raised its holdings in OptimizeRx Co. (NASDAQ:OPRX - Free Report) by 24.0% during the third quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 615,441 shares of the company's stock after acquiring an additional 119,306November 1, 2024 | marketbeat.comOptimizeRx Sets Third Quarter 2024 Conference Call for November 13, 2024 at 4:30 p.m. ETOctober 31, 2024 | globenewswire.com Get OptimizeRx News Delivered to You Automatically Sign up to receive the latest news and ratings for OPRX and its competitors with MarketBeat's FREE daily newsletter. Email Address OPRX Media Mentions By Week OPRX Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. OPRX News Sentiment▼0.630.69▲Average Computer and Technology News Sentiment OPRX News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. OPRX Articles This Week▼32▲OPRX Articles Average Week Get OptimizeRx News Delivered to You Automatically Sign up to receive the latest news and ratings for OPRX and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies CPI Card Group News Bowman Consulting Group News MultiPlan News Rimini Street News National Research News IBEX News trivago News 8X8 News Spree Acquisition Corp. 1 News Nutex Health News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:OPRX) was last updated on 3/3/2025 by MarketBeat.com Staff From Our PartnersURGENT: This Altcoin Opportunity Won’t Wait – Act NowCrypto has officially entered the "banana zone" – that wild phase where prices can 1000x in days. It happen...Crypto Swap Profits | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredUrgent update to my gold outlookTrump’s Policies Are Fueling a Gold Boom—Here’s Your Chance to Profit Donald Trump’s bold policies are driv...Golden Portfolio | Sponsored3 Undervalued Stocks to Get Today (Revealed)These 3 Stocks Should Do Well Even in a Recession If you’re looking for stocks that offer significant upsid...StockEarnings | SponsoredA deadly mistake in my prediction…I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we...Porter & Company | Sponsored“Fed Proof” Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredBefore it hits CNBC: AI was just the warm-up act (see his next prediction)During a routine analysis of my proprietary data, something caught my eye. A small American tech company with ...InvestorPlace | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding OptimizeRx Co. Please log in to your account or sign up in order to add this asset to your watchlist. Share OptimizeRx With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free OPRX Stock Alerts